Subgroups and heterogeneity in cost-effectiveness analysis

PharmacoEconomics

Volumn 26, Issue 9, 2008, Pages 799-806

  Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; AGE DISTRIBUTION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BUDGET; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GROUP DYNAMICS; HEALTH CARE SYSTEM; HEALTH STATISTICS; HUMAN; INDIVIDUALIZATION; POPULATION HETEROGENEITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBGROUP ANALYSIS; UNCERTAINTY; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DELIVERY OF HEALTH CARE; GREAT BRITAIN; HUMANS; MODELS, ECONOMETRIC;

EID: 51149121441     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826090-00009     Document Type: Review

References (20)

1. Claxton K, Briggs A, Buxton M, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251-4
2. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Pol 2007; 12: 56-8
3. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness anaylsis: a framework for establishing efficient limited use criteria. Health Econ 2003; 12: 421-7
4. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 Suppl.: S68-80
5. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
6. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-72
7. Briggs A, Mihaylova B, Sculpher MJ, et al. The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007; 93: 1081-6
8. Henriksson M, Epstein DM, Palmer SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 2008; 94: 717-23
9. Sloan F, Feldman RD, Steinwald AB. Effects of teaching on hospital costs. J Health Econ 1983; 2: 1-28
10. Ramsay CR, Grant AM, Wallace SA, et al. Statistical assessment of the learning curves of health technologies. Health Technol Assess 2001; 5 (12): 1-104
11. Owens DK, Nease RF. A normative analytic framework for development of practice guidelines for specific clinical populations. Med Decis Mak 1997; 17 (4): 409-26
12. Sculpher MJ, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ 2001; 10: 317-24
13. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992 Jan 1; 116 (1): 78-84
14. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 342-64
15. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004
16. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 1997; 16: 2741-58
17. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002; 11: 491-512
18. Bagust A, Grayson A, Palmer N, et al. Cost-effectiveness of a drug-eluting coronary artery stenting in a UK setting: costutility study. Heart 2006; 92 (1): 68-74
19. Epstein DM, Chalabi Z, Claxton K, et al. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Med Dec Making 2007; 27: 128-37
20. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance [draft for public consultation]. London: NICE, 2008